How does SeniorCRE track psychotropic use and gradual dose reduction attempts?

The problem

CMS tracks psychotropic medication use as a quality measure. Most communities cannot tell you their antipsychotic rate without manually counting MARs.

How the platform runs it

Every resident on a psychotropic is flagged. Gradual dose reduction (GDR) candidates are surfaced for prescriber and pharmacist review and outcomes tracked. Behavioral health screening uses validated tools. Non-pharmacological interventions are documented and measured for effectiveness — when something works, the evidence is captured.

On the shift

The psychotropic dashboard lists every resident on an antipsychotic, anxiolytic, or hypnotic with current dose, indication, last GDR attempt, and the next required review date. Mrs. H. is on quetiapine 50 mg HS for sleep — the system flags that her last GDR attempt was 187 days ago and queues a pharmacy-and-physician review. PRN psychotropics show frequency trends; one resident’s lorazepam use has doubled over six weeks, which surfaces in the next behavior committee.

What the outcome looks like

Evidence focus: psychotropic use, GDR attempts, indications, and non-pharmacological interventions are visible for clinical and QAPI review. No quality-measure outcome is claimed here.

What goes wrong without it

Without stewardship infrastructure, psychotropic use creeps. GDR attempts happen when the consultant pharmacist remembers; the documentation supporting the failed attempt is rarely in the chart. F-tags for unnecessary medications follow standard surveys with predictable frequency. The behavioral plan that would have replaced the lorazepam was never written.